J Gynecol Oncol.  2013 Oct;24(4):295-297. 10.3802/jgo.2013.24.4.295.

Potential opportunities to reduce cervical cancer by addressing risk factors other than HPV

• Kumar RV
• Bhasker S

• KMID: 2177869
• DOI: http://doi.org/10.3802/jgo.2013.24.4.295

Abstract

Cervical cancer is the most common cancer in developing world and 80% of global burden is reported from these nations. Human papillomavirus along with poverty, illiteracy/lower education level and standards, multi-parity, tobacco, malnutrition and poor genital hygiene may act synergistically to cause cervical cancer. Risk factor of cervical cancer may in itself be the reason for non-viability of cervical cancer vaccine program in this part of the world. Interventions to address these risk factors in addition to vaccination of girls before their sexual debut may hold promises of reducing the morbidity and mortality of female genital cancers.

Keyword

Cervical cytologic screening; Developing countries; Gynecologic cancers; HPV typing; HPV vaccine

MeSH Terms

Developing Countries
Female
Humans
Hygiene
Literacy
Malnutrition
Poverty
Risk Factors
Tobacco
Uterine Cervical Neoplasms
Vaccination

Reference

1. Horton R. GBD 2010: understanding disease, injury, and risk. Lancet. 2012; 380:2053–2054.

2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–2917.

3. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006; 24:Suppl 3. S3/1–S3/10.

4. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006; 98:303–315.

5. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011; 103:368–383.

6. GlaxoSmithKline Vaccine HPV-007 Study Group. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374:1975–1985.

7. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13:100–110.

8. Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care. 2006; 12:17 Suppl. S462–S472.

9. Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol. 2007; 197:566–571.

10. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011; 128:927–935.

11. Madrid-Marina V, Torres-Poveda K, Lopez-Toledo G, Garcia-Carranca A. Advantages and disadvantages of current prophylactic vaccines against HPV. Arch Med Res. 2009; 40:471–477.

12. PATH. Monitoring ambient and cold chain temperatures during delivery of human papillomavirus vaccine in Vietnam and Uganda. Seattle: World Health Organization, PATH;2010.

13. World Health Organization. The world health report 2005: make every mother and child count. Geneva: World Health Organization;2005.

14. Giard RW, Blok P. Cervical smears unsuitable for exclusion of cervical carcinoma. Ned Tijdschr Geneeskd. 2000; 144:86–87.

15. Castellsague X, Remy V, Puig-Tintore LM, de la Cuesta RS, Gonzalez-Rojas N, Cohet C. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain. J Low Genit Tract Dis. 2009; 13:38–45.